Diclofenac is an anti-inflammatory, analgesic, and antipyretic nonsteroidal anti-inflammatory medication (NSAID) belonging to the phenylacetic acid class. Diclofenac inhibits the cyclooxygenase (COX)-2 enzyme more potently than COX-1, in contrast to the activity of many conventional NSAIDs. Diclofenac has significant dose-dependent gastrointestinal, cardiovascular, and renal side effects, same like other NSAIDs. A variety of diclofenac-containing medication items have been created since its 1973 launch with the intention of enhancing patient convenience, tolerability, and efficacy. In order to improve the safety profile of diclofenac and offer convenient, once-daily dosage for the treatment of patients with chronic pain, delayed- and extended-release versions of diclofenac sodium were first created. Diclofenac potassium salt-containing new medication items were linked to quicker absorption and pain alleviation. These consist of diclofenac potassium powder for oral solution, liquid-filled soft gel capsules, and immediate-release tablets. The development of topical diclofenac formulations made it possible to treat pain and inflammation locally while reducing the drug's systemic absorption. SoluMatrix diclofenac was created to provide analgesic efficacy at lower doses associated with lesser systemic absorption. It is composed of submicron particles of diclofenac free acid and a patented combination of excipients. This paper demonstrates how diclofenac's pharmacokinetic characteristics have been altered by pharmaceutical technology, resulting in the development of innovative therapeutic formulations with enhanced clinical value.